

MAY. 23. 2005 1:39PM

TTC-PA 650-326-2422

NO. 1567 P. 11/18

PTO/SB/ORA (09-03)

Substitute for form 1449A/PTO		Complete If Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,288
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1647
		Examiner Name	Sharon L. Turner
Sheet	2	of	8
		Attorney Docket Number	15270J-004785US

FOREIGN PATENT DOCUMENTS								
Examiner Initials ¹	Cite No. ²	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Paragraphs or Relevant Figures Appear	Y ³
		Country Code ³	Number ⁴	Kind Code ⁵ (if known)				
	533	AU	199870091		07-01-1999			<input type="checkbox"/>
	523	EP	752 888	B1	01-28-1998			<input type="checkbox"/>
	579	WO	04/031400	A2	04-15-2004			<input type="checkbox"/>
	571	WO	04/131172	A2, A3	02-12-2004			<input type="checkbox"/>
	443	WO	03/74081	A1	09-12-2003			<input type="checkbox"/>
	447	WO	03/51374	A2	08-26-2003			<input type="checkbox"/>
	458	WO	02/60481	A1	08-08-2002			<input type="checkbox"/>
	457	WO	02/46237	A1	06-13-2002			<input type="checkbox"/>
	557	WO	02/68307	A2	11-07-2002			<input type="checkbox"/>
	556	WO	02/68308	A2	11-07-2002			<input type="checkbox"/>
	456	WO	02/21141	A2	03-14-2002			<input type="checkbox"/>
	450	WO	01/19169	A3	03-15-2001			<input type="checkbox"/>
	455	WO	01/10900	A2	02-15-2001			<input type="checkbox"/>
	529	WO	00/68263	A2	11-16-2000			<input type="checkbox"/>
	519	WO	00/26238	A2	05-11-2000			<input type="checkbox"/>
	555	WO	00/23082	A1	04-27-2000			<input type="checkbox"/>
	522	WO	00/20027	A2	04-13-2000			<input type="checkbox"/>
	526	WO	99/06567	A2	02-11-1999			<input type="checkbox"/>
	454	WO	98/03815	A1	08-08-1998			<input type="checkbox"/>
	520	WO	98/22120	A1	05-28-1998			<input type="checkbox"/>
	530	WO	98/03668	A1	03-05-1998			<input type="checkbox"/>
	521	WO	98/05350	A1	02-12-1998			<input type="checkbox"/>
	525	WO	98/02462	A1	01-22-1998			<input type="checkbox"/>
	527	WO	97/32017	A1	09-04-1997			<input type="checkbox"/>
	528	WO	97/08320	A1	03-06-1997			<input type="checkbox"/>
	532	WO	96/37821	A2	11-28-1996			<input type="checkbox"/>
	518	WO	95/23186	A1	08-31-1995			<input type="checkbox"/>
	531	WO	95/08999	A1	04-08-1995			<input type="checkbox"/>
	524	WO	95/05393	A2	02-23-1995			<input type="checkbox"/>
	517	WO	94/05311	A1	03-17-1994			<input type="checkbox"/>

Examiner Signature	Date Considered
--------------------	-----------------

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ² Applicant's unique citation designation number (optional). ³ Kind Codes of U.S. Patent Documents at www.uspto.gov or MPEP 601.04. ⁴ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent; place a check mark here if English language Translation is attached. ⁶ Applicant is to place a check mark here if English language Translation is attached.

60497941 v1

MAY. 23. 2005 1:39PM

TTC-PA 650-326-2422

NO. 1567 P. 12/18

PTO/SI/08B (08-03)

Substitute for form 1449B/PTO		Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Application Number	09/724,288
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1647
		Examiner Name	Sharon L. Turner
		Attorney Docket Number	15270J-004785US
Sheet	3	of	8

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	448	ANDREW et al., <i>Current Protocols in Immunology</i> , 2.7.1-2.9.5, John Wiley & Sons, Inc. (1997).	
	484	ARENDIASH et al., "Behavioral assessment of Alzheimer's transgenic mice following long-term A β vaccination: Task specificity and correlations between A β deposition and spatial memory," <i>DNA and Cell Biology</i> , 20(11):737-744 (2001).	
	485	BACSKAI et al., "Imaging of amyloid- β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy," <i>Nature Medicine</i> , 7(3):369-372 (2001).	
	504	BALBACH et al., "Amyloid fibril formation by A β_{1-42} , a seven-residue fragment of the Alzheimer's β -amyloid peptide, and structural characterization by solid state NMR," <i>Biochemistry</i> , 39:13745-13759 (2000).	
	550	BARD et al., "Epitope and isotype specificities of antibodies to β -amyloid peptide for protection against Alzheimer's disease-like neuropathology," <i>PNAS</i> , 100(4):2023-2028 (2003).	
	540	BENKIRANE et al., "Antigenicity and Immunogenicity of Modified Synthetic Peptides Containing D-Amino Acid Residues," <i>J. Biol. Chem.</i> , 268(23):26279-26285 (1993).	
	461	BURDICK et al., "Assembly and aggregation properties of synthetic Alzheimer's A β amyloid peptide antigens," <i>J. Biol. Chem.</i> , 267:543-555 (1992).	
	542	CHISHTI et al., "Early-onset Amyloid Deposition and Cognitive Deficits in Transgenic Mice Expressing a Double Mutant Form of Amyloid Precursor Protein 695," <i>J. Biol. Chem.</i> , 276(24):21562-70 (2001).	
	566	CHOTHIA et al., "Domain Association in Immunoglobulin Molecules," <i>J. Mol. Biol.</i> , 186:651-663 (1985).	
	509	CIRRITO et al., "Amyloid β and Alzheimer disease therapeutics: the devil may be in the details," <i>J. Clin. Invest.</i> , 112:321-323 (2000).	
	482	CO et al., "Chimeric and humanized antibodies with specificity for the CD33 antigen," <i>J. Immunol.</i> , 148:1149-1154 (1992).	
	541	CRIBBS et al., "All-D-Erautomers of Beta-Amyloid Exhibit Similar Biological Properties to All-L-Beta-Amyloids," <i>J. Biol. Chem.</i> , 272:7431-7436 (1997).	
	469	DEMATTOIS et al., "Peripheral anti-A β antibody alters CNS and plasma clearance and decreases A β burden in a mouse model of Alzheimer's disease," <i>PNAS</i> , 98(15):8850-8855 (2001).	
	493	DEMATTOIS et al., "Plaque-associated disruption of CSF and plasma amyloid- β (A β) equilibrium in a mouse model of Alzheimer's disease," <i>J. Neurochem.</i> , 81:229-236 (2002).	
	486	DICKEY et al., "Duration and specificity of humoral immune responses in mice vaccinated with the Alzheimer's disease-associated β -amyloid 1-42 peptide," <i>DNA and Cell Biology</i> , 20(11):723-729 (2001).	

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw the through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language translation is attached.

60497941 v1

MAY. 23. 2005 1:40PM

TTC-PA 650-326-2422

NO. 1567 P. 13/18

PTOGB/08B (08-03)

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/724,288	
			Filing Date	November 28, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1647	
			Examiner Name	Sharon L. Turner	
Sheet	4	of	8	Attorney Docket Number	15270J-004785US

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	475	EL-AGNAF et al., "The influence of the central region containing residues 19-25 on the aggregation properties and secondary structure of Alzheimer's beta-amyloid peptide," <i>Eur. J. Biochem.</i> , 256(3):560-568 (1996).	
	501	ESLER et al., "Point substitution in the central hydrophobic cluster of a human β -amyloid congener disrupts peptide folding and abolishes plaque competence," <i>Biochemistry</i> , 35:13914-13921 (1996).	
	539	FINDEIS et al., "Modified peptide inhibitors of amyloid β -peptide polymerization," <i>Biochemistry</i> , 38:6791-6800 (1999).	
	464	FLOOD et al., "An amyloid β -Protein fragment, A β [12-28], equipotently impairs post-training memory processing when injected into different limbic system structures," <i>Brain Res.</i> , 663(2):271-276 (1994).	
	538	FLOOD, et al., "Topography of a binding site for small amnesic peptides deduced from structure-activity studies: Relation to amnesic effect of amyloid β protein," <i>PNAS</i> , 91:390-394 (1994).	
	595	FRAZER et al., "Immunoglobulins: Structure and Function," chapter 3, pages 37-74 from <i>Fundamental Immunology</i> , fourth edition, W.E. Paul, eds., Lippincott-Raven publishers, Philadelphia (1990).	
	463	GHISO et al., "Epitope map of two polyclonal antibodies that recognize amyloid lesions in patients with Alzheimer's disease," <i>Biochem. J.</i> , 282 (Pt 2):517-522 (1992).	
	470	GIULIAN et al., "Specific domains of β -amyloid from Alzheimer plaque elicit neuron killing in human microglia," <i>J. Neurosci.</i> , 16 (19):6021-6037 (1996).	
	503	GOREVIC et al., "Ten to fourteen residue peptides of Alzheimer's disease protein are sufficient for amyloid fibril formation and its characteristic X ray diffraction pattern" <i>Biochem. and Biophys. Res. Commun.</i> , 147(2):854-862 (1987).	
	487	HAASS et al., "Protofibrils, the unifying toxic molecule of neurodegenerative disorders?," <i>Nature Neuroscience</i> , 4(9):859-860 (2001).	
	476	HE et al., "Humanization and pharmacokinetics of a monoclonal antibody with specificity for both E- and P-selectin," <i>J. Immunol.</i> , 160:1029-1035 (1998).	
	473	HILBICH et al., "Aggregation and secondary structure of synthetic amyloid β A4 peptides of Alzheimer's disease," <i>J. Mol. Biol.</i> , 218:149-163 (1991).	
	471	HILBICH et al., "Substitutions of hydrophobic amino acid reduce the amyloidogenicity of Alzheimer's disease β A4 peptides" <i>J. Mol. Biol.</i> , 228:460-473 (1992).	
	534	HOCK et al., "Antibodies against β -Amyloid Slow Cognitive Decline in Alzheimer's Disease," <i>Neuron</i> , 38:542-554 (2003).	
	546	IRIZARRY et al., "A β Deposition Is Associated with Neuropil Changes, but not with Overt Neuronal Loss in the Human Amyloid Precursor Protein V717F (PDAPP) Transgenic Mouse," <i>J. Neuroscience</i> , 17(16):7053-7059 (1997).	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 909. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

60497941 v1

MAY. 23. 2005 1:40PM

TTC-PA 650-326-2422

NO. 1567 P. 14/18

PTO/SB/069 (06-02)

Substitute for form 1449B/PTO			Complete if Known		
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/724,288	
			Filing Date	November 28, 2000	
			First Named Inventor	Schenk, Dale B.	
			Art Unit	1647	
			Examiner Name	Sharon L. Turner	
			Attorney Docket Number	15270J-004765US	
Sheet	5	of	8		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	449	JOHNSON-WOOD et al., "Amyloid precursor protein processing and A β ₄₂ deposition in a transgenic mouse model of Alzheimer disease," <i>PNAS</i> , 94:1550-1555 (1997).		
	547	KAYED et al., "Conformational Transitions of Isetl Amyloid Polypeptide (IAPP) in Amyloid Formation In Vitro," <i>J. Mol. Biol.</i> , 267:781-796 (1999).		
	554	KETTLERBOROUGH et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <i>Protein Engineering</i> , 4(7):773-783 (1991).		
	488	KLEIN et al., "Targeting small A β oligomers: the solution to an Alzheimer's disease conundrum?," <i>Trends in Neurosciences</i> , 24(4):219-224 (2001).		
	494	KOTILINEK et al., "Reversible memory loss in a mouse transgenic model of Alzheimer's disease," <i>J. Neurosci.</i> , 22(15):6331-6335 (2002).		
	465	KOUDINOV et al., "The soluble form of Alzheimer's amyloid beta protein is complexed to high density lipoprotein 3 and very high density lipoprotein in normal human plasma," <i>Biochem. & Biophys. Res. Comm.</i> , 205:1164-1171 (1994).		
	478	KUO et al., "High levels of circulating Abeta42 are sequestered by plasma proteins in Alzheimer's disease," <i>Biochem. Biophys. Res. Comm.</i> , 257(3):787-791 (1999).		
	477	LAMBERT et al., "Diffusible, nonfibrillar ligands derived from A β 1-42 are potent central nervous system neurotoxins," <i>PNAS</i> , 95:6448-6453 (1998).		
	489	LAMBERT et al., "Vaccination with soluble A β oligomers generates toxicity-neutralizing antibodies," <i>J. Neurochem.</i> , 79:595-605 (2001).		
	490	LEE et al., "A β immunization: Moving A β peptide from brain to blood," <i>PNAS</i> , 98(16):8931-8932 (2001).		
	553	LEMBRE et al., "Intranasal immunotherapy for the treatment of Alzheimer's disease: Escherichia coli LT and LT(R192G) as mucosal adjuvants," <i>Neurobiology of Aging</i> , 23(6):991-1000 (2002).		
	551	LEVERONE et al., "A β 1-15 is less immunogenic than A β 1-4042 for intranasal immunization of wild-type mice but may be effective for boosting," <i>Vaccine</i> , 21:2197-2205 (2003).		
	459	LEVITT, M., "Molecular dynamics of native protein," <i>J. Mol. Biol.</i> , 168:595-620 (1983).		
	481	LEVY et al., "Immunization for Alzheimer's disease: A shot in the arm or a whiff?," <i>American Neurological Assoc.</i> , 48:553-554 (2000).		
	499	LUE et al., "Soluble β -amyloid Peptide Concentration as a Predictor of Synaptic Change in Alzheimer's Disease," <i>Am. J. Pathol.</i> , 155:853-862 (1999).		

Examiner Signature	Date Considered
--------------------	-----------------

* EXAMINER: initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicants.

* Applicant's unique citation designation number (optional). * Applicant to place a check mark here if English language Translation is attached.

60497941 v1

MAY. 23. 2005 1:40PM

TTC-PA 650-326-2422

NO. 1567 P. 15/18

PTO/SB/03B (08-03)

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/724,288
			Filing Date	November 28, 2000
			First Named Inventor	Schenk, Dale B.
			Art Unit	1647
			Examiner Name	Sharon L. Turner
			Attorney Docket Number	15270J-004765US
Sheet	6	of	8	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. 1	include name of the author (in CAPITAL LETTERS); title of the article (when appropriate); title of the item (book, magazine, journal, serial, symposium, catalog, etc.); date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	502	MAGGIO et al., "Brain Amyloid - A Physicochemical Perspective," <i>Brain Pathology</i> , 6:147-162 (1996).		
	545	MASLIAH et al., "Comparison of Neurodegenerative Pathology in Transgenic Mice Overexpressing V717F β -Amyloid Precursor Protein and Alzheimer's Disease," <i>J. Neuroscience</i> , 19(18):5795-5811 (1999).		
	479	MCLEAN et al., "Soluble pool of A β amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease," <i>Amer. Neurological Assoc.</i> , 45:850-855 (1999).		
	482	NASLUND et al., "Correlation between elevated levels of amyloid β peptide in the brain and cognitive decline," <i>J. Am. Med. Assoc.</i> , 283:1571 (2000).		
	558	NOVOTNY et al., "Structural invariants of antigen binding: Comparison of Immunoglobulin V _L -V _H and V _L -V _L domain dimers," <i>PNAS</i> , 82:4592-4596 (1985).		
	564	PCT Search Report of 12/14/04 for application PCT/US04/02856		
	491	PODUSLO et al., "Permeability of proteins at the blood-brain barrier in the normal adult mouse and double transgenic mouse model of Alzheimer's disease," <i>Neurobiol. Dis.</i> , 6(4):555-567 (2001).		
	460	QUEEN et al., "A humanized antibody that binds to the interleukin 2 receptor," <i>PNAS</i> , 86:10029-10033 (1989).		
	497	RAGUSI et al., "Redistribution of Imipramine from Regions of the Brain Under the Influence of Circulating Specific Antibodies," <i>J. Neurochem.</i> , 70(5):2059-2105 (1998).		
	466	SCHWARZMAN et al., "Transferrin sequesters amyloid β protein and prevents amyloid formation," <i>PNAS</i> , 91:8368-8372 (1994).		
	536	SELA et al., "Different roles of D-amino acids in immune phenomena," <i>FASEB J.</i> , 11(6):449-456 (1998).		
	552	SIGURDSSON et al., "Immunization with a Nontoxic/Nonfibrillar Amyloid- β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice," <i>Am. J. Pathology</i> , 159(2):439-447 (2001).		
	505	SIMMONS, L., "Secondary structure of amyloid β peptide correlates with neurotoxic activity <i>in vitro</i> ," <i>Molecular Pharmacology</i> , 45:373-379 (1994).		
	549	SOLOMON, S., "Immunological approaches as therapy for Alzheimer's disease," <i>Expert Opin. Biol. Ther.</i> , 2(8):907-917 (2002).		
	508	SOTO et al., "The α -helical to β -strand transition in the amino-terminal fragment of the amyloid β -peptide modulates amyloid formation," <i>J. Biol. Chem.</i> , 270(7):3063-3067 (1995).		

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 608. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

* Applicant's unique citation designation number (optional). * Applicant is to place a check mark here if English language Translation is attached.

60497941 v1

PTO/SB/03B (01-03)

Substitute for form 1449B/PTO			Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Application Number	09/724,288
			Filing Date	November 28, 2000
			First Named Inventor	Schenk, Dale B.
			Art Unit	1647
			Examiner Name	Sharon L. Turner
			Attorney Docket Number	15270J-004765US
Sheet	7	of	8	

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²	
	496	STRBAK et al., "Passive Immunization and Hypothalamic Peptide Secretion", <i>Neuroendocrinology</i> , 58:210-217 (1993).		
	498	SUC et al., "Soluble Alzheimers β -amyloid constricts the cerebral vasculature in vivo" <i>Neuroscience Letters</i> , 257:77-80 (1998).		
	467	TABATON et al., "Soluble amyloid β -protein is a marker of Alzheimer amyloid in brain but not in cerebrospinal fluid," <i>Biochem. and Biophys. Res. Comm.</i> , 200(3):1598-1603 (1994).		
	472	TELLER et al., "Presence of soluble amyloid β -peptide precedes amyloid plaque formation in Down's syndrome" <i>Nature Medicine</i> , 2(1):93-95 (1996).		
	500	TJERNBERG et al., "A molecular model for Alzheimer amyloid β -peptide fibril formation," <i>J. Biol. Chem.</i> , 274(18):12619-12623 (1999).		
	537	TJERNBERG, et al., "Controlling amyloid beta-peptide fibril formation with protease-stable ligands," <i>J. Biol. Chem.</i> , 272(19):12601-12605 (1997).		
	492	TOWN et al., "Characterization of murine immunoglobulin G antibodies against human amyloid- β_{1-42} " <i>Neurosci. Lett.</i> , 307:101-104 (2001).		
	535	VAN REGENMORTEL et al., "D-peptides as immunogens and diagnostic reagents," <i>Curr. Opin. Biotechnol.</i> , 9(4):377-382 (1998).		
	569	VERSHIGORA A. E. OBSHCAYA IMMUNOLOGIYA, pages 35, 229-231 and 152-153, 1990		
	480	WANG et al., "The levels of soluble versus insoluble brain A β distinguish Alzheimer's disease from normal and pathologic aging," <i>Experimental Neurology</i> , 158:328-337 (1999).		
	495	WANG et al., "Soluble oligomers of β amyloid (1-42) inhibit long-term potentiation but not long-term depression in rat dentate gyrus," <i>Brain Research</i> , 924:133-140 (2002).		
	474	WINTER et al., "Humanized antibodies" <i>Immunology Today</i> , 14(6):243-246 (1996).		
	468	WISNIEWSKI et al., "Alzheimer's disease and soluble A beta," <i>Neurobiol. Aging</i> , 15(2):143-52 (1994).		
	506	WOOD et al., "Prolines and amyloidogenicity in fragments of the Alzheimer's peptide pA4" <i>Biochemistry</i> , 34:724-730 (1995).		
	567	WU et al., "An Analysis of the Sequences of the Variable Regions of Bence Jones Proteins and Myeloma Light Chains and their Implications for Antibody Complementarity," <i>J. Exp. Med.</i> , 152:211-250 (1970).		
	507	XU et al., "Increased incidence of anti- β -amyloid autoantibodies secreted by Epstein-Barr virus transformed B cell lines from patients with Alzheimer's disease," <i>Mechanisms of Aging and Development</i> , 84:213-222 (1997).		

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

60497941 v1

MAY. 23. 2005 1:41PM

TTC-PA 650-326-2422

NO. 1567 P. 17/18

PTO/SB/01B (01-03)

Substitute for form 1448B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known Application Number 09/724,288 Filing Date November 28, 2000 First Named Inventor Schenk, Dale B. Art Unit 1647 Examiner Name Sharon L. Turner Attorney Docket Number 15270J-004765US		
Sheet	8	of	8		

NON PATENT LITERATURE DOCUMENTS				
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issues number(s), publisher, city and/or country where published.	T ²	
	483	ZLOKOVIC et al., "Clearance of amyloid β -peptide from brain: transport or metabolism?", <u>Nature Medicine</u> , 6(7):718-719 (2000).		
	580	ZLOKOVIC et al., "Glycoprotein 330/megalin: probable role in receptor-mediated transport of apolipoprotein J alone and in a complex with Alzheimer disease amyloid beta at the blood-brain and blood-cerebrospinal fluid barriers." <u>PNAS</u> , 93(9):4229-4334 (1996) abstract only.		

Examiner Signature	/Daniel Kolker/	Date Considered	03/18/2009
-----------------------	-----------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
 *Applicant's unique citation designation number (optional). *Applicant is to place a check mark here if English language Translation is attached.

60497941 v1